Trevena Inc (NASDAQ:TRVN) Expected to Post Earnings of -$0.08 Per Share

Wall Street analysts expect Trevena Inc (NASDAQ:TRVN) to report ($0.08) earnings per share (EPS) for the current quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Trevena’s earnings. Trevena reported earnings of ($0.10) per share in the same quarter last year, which would suggest a positive year-over-year growth rate of 20%. The firm is scheduled to announce its next quarterly earnings results on Wednesday, March 11th.

On average, analysts expect that Trevena will report full year earnings of ($0.28) per share for the current financial year. For the next financial year, analysts anticipate that the company will post earnings of ($0.34) per share. Zacks’ earnings per share averages are a mean average based on a survey of research firms that follow Trevena.

Trevena (NASDAQ:TRVN) last issued its earnings results on Monday, November 4th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.08) by ($0.01).

TRVN has been the subject of a number of research analyst reports. HC Wainwright reaffirmed a “buy” rating and set a $3.50 price objective on shares of Trevena in a research report on Tuesday, November 5th. Zacks Investment Research cut shares of Trevena from a “hold” rating to a “sell” rating in a research report on Tuesday. Finally, ValuEngine raised shares of Trevena from a “sell” rating to a “hold” rating in a research report on Tuesday, December 3rd.

A number of hedge funds have recently added to or reduced their stakes in the business. Vanguard Group Inc. boosted its position in Trevena by 11.5% during the second quarter. Vanguard Group Inc. now owns 3,915,315 shares of the biopharmaceutical company’s stock worth $4,032,000 after purchasing an additional 403,060 shares during the period. BlackRock Inc. boosted its position in Trevena by 1.9% during the second quarter. BlackRock Inc. now owns 2,647,830 shares of the biopharmaceutical company’s stock worth $2,727,000 after purchasing an additional 49,900 shares during the period. Renaissance Technologies LLC boosted its position in shares of Trevena by 50.2% in the second quarter. Renaissance Technologies LLC now owns 1,928,850 shares of the biopharmaceutical company’s stock valued at $1,987,000 after acquiring an additional 644,812 shares during the period. Morgan Stanley boosted its position in shares of Trevena by 2,651.1% in the second quarter. Morgan Stanley now owns 530,436 shares of the biopharmaceutical company’s stock valued at $546,000 after acquiring an additional 511,155 shares during the period. Finally, JPMorgan Chase & Co. bought a new stake in shares of Trevena in the second quarter valued at about $264,000. 20.42% of the stock is owned by hedge funds and other institutional investors.

TRVN stock opened at $0.72 on Wednesday. The company has a debt-to-equity ratio of 0.23, a current ratio of 3.31 and a quick ratio of 3.31. The company has a fifty day moving average price of $0.79 and a two-hundred day moving average price of $0.93. Trevena has a one year low of $0.38 and a one year high of $2.00. The stock has a market cap of $66.76 million, a price-to-earnings ratio of -1.71 and a beta of 2.54.

Trevena Company Profile

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of treatment options that target and treat diseases affecting the central nervous system. Its product candidates include Oliceridine injection, a G protein biased mu-opioid receptor (MOR) ligand that has completed Phase III clinical trials for the management of moderate-to-severe acute pain where intravenous administration is warranted; TRV250, a G protein biased delta- opioid receptor ligand, which is in Phase I clinical study for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR that has completed Phase I clinical study for the treatment of moderate-to-severe acute and chronic pain; TRV027 for the treatment of acute heart failure; and TRV045, a novel S1P modulator for managing chronic pain.

Featured Story: What is a conference call?

Get a free copy of the Zacks research report on Trevena (TRVN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Trevena (NASDAQ:TRVN)

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.